Drug-induced liver injury after switching from tamoxifen to anastrozole in a patient with a history of breast cancer being treated for hypertension and diabetes
Anastrozole is a selective non-steroidal aromatase inhibitor that blocks the conversion of androgens to estrogens in peripheral tissues. It is used as adjuvant therapy for early-stage hormone-sensitive breast cancer in postmenopausal women. Significant side effects of anastrozole include osteoporosi...
Main Authors: | Petr Potmešil, Radka Szotkowská |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-11-01
|
Series: | Therapeutic Advances in Chronic Disease |
Online Access: | https://doi.org/10.1177/2040622320964152 |
Similar Items
-
Corrigendum to “Drug-induced liver injury after switching from tamoxifen to anastrozole in a patient with a history of breast cancer being treated for hypertension and diabetes”
Published: (2021-04-01) -
Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice.
by: Anna Kemp, et al.
Published: (2014-01-01) -
Anastrozole and Tamoxifen Impact on IgG Glycome Composition Dynamics in Luminal A and Luminal B Breast Cancers
by: Borna Rapčan, et al.
Published: (2024-02-01) -
Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial
by: Li J, et al.
Published: (2018-12-01) -
Effects of switching from anastrozole to letrozole, due to reimbursement policy, on the outcome of breast cancer therapy
by: Aphinives P, et al.
Published: (2014-08-01)